News
RVPH
0.340
0.00%
0.000
Reviva Pharmaceuticals GAAP EPS of -$0.17 beats by $0.23
Seeking Alpha · 14h ago
Reviva Pharmaceuticals Q3 EPS $(0.17) Beats $(0.29) Estimate
Benzinga · 14h ago
Press Release: Reviva Reports Third Quarter 2026 -2-
Dow Jones · 18h ago
Press Release: Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Dow Jones · 18h ago
Weekly Report: what happened at RVPH last week (1102-1106)?
Weekly Report · 4d ago
Weekly Report: what happened at RVPH last week (1026-1030)?
Weekly Report · 11/02 09:59
Weekly Report: what happened at RVPH last week (1019-1023)?
Weekly Report · 10/26 09:59
Two new option listings and eleven option delistings on October 19th
TipRanks · 10/19 12:36
Weekly Report: what happened at RVPH last week (1012-1016)?
Weekly Report · 10/19 09:59
Weekly Report: what happened at RVPH last week (1005-1009)?
Weekly Report · 10/12 10:03
Weekly Report: what happened at RVPH last week (0928-1002)?
Weekly Report · 10/05 10:03
Weekly Report: what happened at RVPH last week (0921-0925)?
Weekly Report · 09/28 09:59
Weekly Report: what happened at RVPH last week (0914-0918)?
Weekly Report · 09/21 09:59
Weekly Report: what happened at RVPH last week (0907-0911)?
Weekly Report · 09/14 10:03
Weekly Report: what happened at RVPH last week (0831-0904)?
Weekly Report · 09/07 09:58
Weekly Report: what happened at RVPH last week (0824-0828)?
Weekly Report · 08/31 10:04
Weekly Report: what happened at RVPH last week (0817-0821)?
Weekly Report · 08/24 10:04
Weekly Report: what happened at RVPH last week (0810-0814)?
Weekly Report · 08/17 10:05
OTC Market Listing Exposes Reviva Pharmaceuticals to Volatility, Illiquidity and Pricing Risks
TipRanks · 08/14 06:00
Reviva Pharmaceuticals Q2 EPS $(0.19) Beats $(0.39) Estimate
Benzinga · 08/12 22:00
More
Webull provides a variety of real-time RVPH stock news. You can receive the latest news about Reviva Pharmaceutcls Hldgs Inc through multiple platforms. This information may help you make smarter investment decisions.
About RVPH
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).